CHARLOTTESVILLE, Va., Feb. 13, 2024 Adial Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and.
Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Adial Pharmaceuticals Inc (NASDAQ: ADIL) has been awarded a key patent combining the use of the company's proprietary genetic diagnostic to detect select genotypes for genetically targeted treatment of alcohol use disorder (AUD) and opioid use disorder (OUD) with the company's lead investigatio
Adial Pharmaceuticals Inc (NASDAQ: ADIL) has been awarded a key patent combining the use of the company's proprietary genetic diagnostic to detect select genotypes for genetically targeted treatment of alcohol use disorder (AUD) and opioid use disorder (OUD) with the company's lead investigational product AD04. AD04 is a genetically targeted, serotonin-3 receptor antagonist therapeutic agent for Alcohol Use Disorder in heavy drinking patients. "This patent marks another important milestone in ou
Adial Pharmaceuticals, Inc : Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.